Meet Jeff Smith, the hedge-fund investor taking on Pfizer
Briefly

Starboard Value's investment in Pfizer sends a signal to management that streamlining and strategic improvements are likely necessary for long-term success.
Starboard’s strategy is not yet decided, but its history suggests it will seek to maximize share value through potential board influence and operational efficiencies.
With a valuation of $1 billion, Starboard enters as a major player in Pfizer’s future, aiming to drive operational changes that could bolster revenue.
The support from former Pfizer executives positions Starboard favorably, indicating a collaborative approach to potential restructuring or operational reforms.
Read at Business Insider
[
|
]